Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Jiping WangMonica M Bertagnolli

Abstract

Background: The Adenoma Prevention with Celecoxib (APC) Trial showed that cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, decreased adenoma development in patients at high risk for colorectal cancer. A prospectively planned analysis of the APC Trial tested the hypothesis that expression of target enzymes in adenomas removed before beginning study treatment would identify individuals at high risk of adenoma development, and/or predict response to Cox-2 inhibition.Methods: Pre-treatment adenomas were examined using immunohistochemistry to assess expression of Cox-2 (high vs. low) and 15-prostaglandin dehydrogenase (15-PGDH, presence vs. loss). The Mantel-Cox test evaluated whether these markers predicted benefit from celecoxib for reduction of adenoma detection.Results: Patients whose pre-treatment adenomas demonstrated elevated Cox-2 achieved the greatest adenoma reduction with celecoxib treatment [RR, 0.37; 95% confidence interval (CI), 0.22-0.61; P = 0.0001]. This reduction was less in the low Cox-2 category (RR, 0.64; 95% CI, 0.56-0.73). Patients whose pre-treatment adenomas showed 15-PGDH loss had a similar treatment-associated reduction in adenoma detection (RR, 0.60; 95% CI, 0.52-0.69; P < 0.0001). In contrast, patients wit...Continue Reading

References

Dec 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Min YanSanford D Markowitz
Feb 17, 2005·The New England Journal of Medicine·Scott D SolomonUNKNOWN Adenoma Prevention with Celecoxib (APC) Study Investigators
Aug 2, 2006·Proceedings of the National Academy of Sciences of the United States of America·Seung-Jae MyungSanford D Markowitz
Sep 1, 2006·The New England Journal of Medicine·Monica M BertagnolliUNKNOWN APC Study Investigators
Sep 1, 2006·The New England Journal of Medicine·Nadir ArberUNKNOWN PreSAP Trial Investigators
May 15, 2007·Lancet·Enrico FlossmannUNKNOWN British Doctors Aspirin Trial and the UK-TIA Aspirin Trial
Jan 14, 2009·Cancer Prevention Research·Nancy L ChoMonica M Bertagnolli
Apr 2, 2009·Cancer Prevention Research·Monica M BertagnolliUNKNOWN Adenoma Prevention with Celecoxib Study Investigators
May 28, 2009·Proceedings of the National Academy of Sciences of the United States of America·Min YanSanford D Markowitz
Dec 19, 2009·The New England Journal of Medicine·Sanford D Markowitz, Monica M Bertagnolli
Nov 30, 2011·Best Practice & Research. Clinical Gastroenterology·Brian Kim, Francis M Giardiello
Apr 30, 2013·Digestive Diseases and Sciences·Stephen P FinkSeung-Jae Myung
Jun 16, 2016·JAMA : the Journal of the American Medical Association·UNKNOWN US Preventive Services Task ForceAlbert L Siu
Dec 14, 2016·The New England Journal of Medicine·Steven E NissenUNKNOWN PRECISION Trial Investigators
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Nov 8, 2018·Nutrients·Nour YahfoufiChantal Matar
Mar 4, 2020·International Journal of Oncology·Romina Gabriela ArmandoDaniel Eduardo Gomez
Aug 12, 2018·International Journal of Molecular Sciences·Altaf MohammedChinthalapally V Rao
Sep 30, 2019·Gastroenterology·Bryson W Katona, Jennifer M Weiss
Dec 23, 2020·International Journal of Molecular Sciences·Nagendra S YarlaChinthalapally V Rao
Apr 20, 2020·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Xiaoyun TangDavid N Brindley
Apr 4, 2021·Cancers·Kritika PrasaiAmit Mahipal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.